Latest Breaking News On - Myeloma investment fund - Page 4 : comparemela.com

Sanofi pays $160m upfront to acquire Tidal Therapeutics French pharma company s acquisition of pre-clinical stage biotech includes mRNA-based research platform French pharma company Sanofi has announced its acquisition of pre-clinical stage biotech company Tidal Therapeutics, which is focused on mRNA-based research. Tidal’s mRNA-based research platform has potential in a number of disease areas – including oncology and immunology – according to Sanofi. Sanofi has paid $160m upfront to acquire Tidal, with up to $310m contingent on the achievement of future milestones. Following the acquisition, Sanofi will gain access to Tidal’s novel mRNA-based approach to in vivo reprogramming of immune cells.

United kingdomUnited statesFrank nestleMerck co keytrudaEnterprise associatesMyeloma investment fundMission biocapitalMyeloma research foundationTidal therapeuticsNew enterprise associatesMultiple myeloma research foundationஒன்றுபட்டது கிஂக்டம்ஒன்றுபட்டது மாநிலங்களில்வெளிப்படையான கூடுநிறுவன கூட்டாளிகள்மைலோமா ஆராய்ச்சி அடித்தளம்